Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates
Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.17 per share a year ago.
Can Weight-Loss Momentum Lift Hims & Hers Stock Before Q2 Earnings?
HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) closed at $31.65 in the latest trading session, marking a -1.59% move from the prior day.
Hims & Hers Health: Still An Undervalued Company With Tremendous Upside
Hims & Hers Health remains deeply undervalued despite a 578% stock gain since 2022, with fundamentals vastly improved. HIMS is projected to reach $3.5B revenue in 2026 and potentially $9B by 2030, driven by GLP-1 adoption, peptides, and international expansion. Insider and institutional ownership have increased, margins remain robust at 73%, and subscriber growth is accelerating, especially via the Novo partnership.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.32, indicating a -3.04% shift from the previous trading day.
Understanding The AI Flywheel At Hims And Hers
Hims & Hers is a subscriber-based online healthcare provider that operates outside of the traditional paradigm. Its AI-native processes and visibility to each patient's full medical journey create a flywheel that's difficult for competitors to replicate. Its moat is further enhanced by its vertical integration and scale.
Hims & Hers: Peptide Ruling A Positive, Operational Good Sense Makes 'Buy' Case (Upgrade)
Hims & Hers Health is upgraded from "Hold" to "Buy," driven by operational discipline and strategic opportunism despite sector volatility. HIMS leverages FDA panel momentum on peptides, expanding into personalized treatments while maintaining a robust telehealth platform and global reach. Management pursues a "best in market" approach to peptide launches, prioritizing clinical rigor, validated supply chains, and data transparency over speed.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.68, moving 3.21% from the previous trading session.
Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.15, moving +2.24% from the previous trading session.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Health: The Market Still Doesn't Get It
FDA staff challenged seven compounded peptides, but Hims & Hers continues expanding internationally and strengthening its core healthcare platform beyond longevity therapies. The $400 million JPMorgan receivables facility improves financial flexibility, supporting GLP-1 expansion without relying on dilutive equity financing. The $1.15 billion Eucalyptus acquisition adds 850,000 customers and approximately $450 million of ARR across eight international markets.
